Literature DB >> 34448096

The application of oncolytic viruses in cancer therapy.

Yang Gao1, Yan Wu1, Tian Huan1, Xiaoyan Wang2, Jun Xu3, Qinggang Xu1, Feng Yu4, Haifeng Shi5.   

Abstract

Oncolytic therapy is a treatment method used to directly combat tumor cells by modifying the genes of naturally occurring low pathogenic viruses to form "rhizobia" virus. By taking the advantage of abnormal signal pathways in cancer cells, it selectively replicates in tumor cells leading to tumor cell lysis and death. At present, clinical studies widely employ biomolecular technology to transform oncolytic viruses to exert stronger oncolytic effects and reduce their adverse reactions. This review summarizes the current progresses and the molecular mechanism of oncolytic viruses towards tumor treatment and management.
© 2021. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Cancer therapy; Immune response; Molecular mechanism; Oncolytic virus

Mesh:

Year:  2021        PMID: 34448096     DOI: 10.1007/s10529-021-03173-3

Source DB:  PubMed          Journal:  Biotechnol Lett        ISSN: 0141-5492            Impact factor:   2.461


  47 in total

1.  Editorial overview: Oncolytic viruses--replicating virus therapeutics for the treatment of cancer.

Authors:  John C Bell; Grant McFadden
Journal:  Curr Opin Virol       Date:  2015-08-07       Impact factor: 7.090

Review 2.  Targeting B7-1 in immunotherapy.

Authors:  Rui Chen; Aravindhan Ganesan; Isobel Okoye; Elena Arutyunova; Shokrollah Elahi; M Joanne Lemieux; Khaled Barakat
Journal:  Med Res Rev       Date:  2019-08-25       Impact factor: 12.944

Review 3.  Integrating oncolytic viruses in combination cancer immunotherapy.

Authors:  Praveen K Bommareddy; Megha Shettigar; Howard L Kaufman
Journal:  Nat Rev Immunol       Date:  2018-08       Impact factor: 53.106

4.  Cytosolic activation of cathepsins mediates parvovirus H-1-induced killing of cisplatin and TRAIL-resistant glioma cells.

Authors:  Matteo Di Piazza; Carmen Mader; Karsten Geletneky; Marta Herrero Y Calle; Ekkehard Weber; Jörg Schlehofer; Laurent Deleu; Jean Rommelaere
Journal:  J Virol       Date:  2007-02-07       Impact factor: 5.103

Review 5.  Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination.

Authors:  Celine Boutros; Ahmad Tarhini; Emilie Routier; Olivier Lambotte; Francois Leroy Ladurie; Franck Carbonnel; Hassane Izzeddine; Aurelien Marabelle; Stephane Champiat; Armandine Berdelou; Emilie Lanoy; Matthieu Texier; Cristina Libenciuc; Alexander M M Eggermont; Jean-Charles Soria; Christine Mateus; Caroline Robert
Journal:  Nat Rev Clin Oncol       Date:  2016-05-04       Impact factor: 66.675

6.  The oncolytic activity of Newcastle disease virus in clear cell renal carcinoma cells in normoxic and hypoxic conditions: the interplay between von Hippel-Lindau and interferon-β signaling.

Authors:  Wei-Choong Ch'ng; Eric J Stanbridge; Khatijah Yusoff; Norazizah Shafee
Journal:  J Interferon Cytokine Res       Date:  2013-03-18       Impact factor: 2.607

7.  Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.

Authors:  Jason Chesney; Igor Puzanov; Frances Collichio; Parminder Singh; Mohammed M Milhem; John Glaspy; Omid Hamid; Merrick Ross; Philip Friedlander; Claus Garbe; Theodore F Logan; Axel Hauschild; Celeste Lebbé; Lisa Chen; Jenny J Kim; Jennifer Gansert; Robert H I Andtbacka; Howard L Kaufman
Journal:  J Clin Oncol       Date:  2017-10-05       Impact factor: 44.544

Review 8.  PAMPs, PRRs, effectors and R-genes associated with citrus-pathogen interactions.

Authors:  Ronaldo J D Dalio; Diogo M Magalhães; Carolina M Rodrigues; Gabriella D Arena; Tiago S Oliveira; Reinaldo R Souza-Neto; Simone C Picchi; Paula M M Martins; Paulo J C Santos; Heros J Maximo; Inaiara S Pacheco; Alessandra A De Souza; Marcos A Machado
Journal:  Ann Bot       Date:  2017-03-01       Impact factor: 4.357

9.  MicroRNA silencing improves the tumor specificity of adenoviral transgene expression.

Authors:  P B Card; R T Hogg; C R Gil Del Alcazar; R D Gerard
Journal:  Cancer Gene Ther       Date:  2012-05-04       Impact factor: 5.987

10.  In vivo bioimaging tracks conditionally replicative adenoviral replication and provides an early indication of viral antitumor efficacy.

Authors:  Julia Davydova; Tatyana Gavrikova; Eric J Brown; Xianghua Luo; David T Curiel; Selwyn M Vickers; Masato Yamamoto
Journal:  Cancer Sci       Date:  2009-10-20       Impact factor: 6.716

View more
  1 in total

1.  Viruses: Friends or foes.

Authors:  Carmen Michán; Alfredo Michán-Doña
Journal:  Microb Biotechnol       Date:  2021-10-11       Impact factor: 5.813

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.